

IN THE CLAIMS

Please amend the claims as follows. Applicant has included herewith a complete claim set with insertions and deletions indicated by underlining and double bracketing, respectively.

1. (Withdrawn) A medicament having cytokine suppression effect, comprising as an active ingredient at least one of riboflavin, a riboflavin derivative or a pharmacologically acceptable salt thereof.
2. (Withdrawn) The medicament according to Claim 1, which is useful for preventing or treating hypercytokinemia.
3. (Withdrawn) The medicament according to Claim 1, which is useful for preventing or treating systemic inflammatory response syndrome.
4. (Withdrawn) The medicament according to Claim 3, wherein said systemic inflammatory response syndrome is not caused by an infection.
5. (Withdrawn) The medicament according to Claim 4, wherein said systemic inflammatory response syndrome is caused by a wound, a burn, pancreatitis, liver damage, ischemia/reperfusion injury or surgery.
6. (Withdrawn) The medicament according to any one of Claims 1 through 5, wherein said cytokine suppression effect suppresses at least one of IL-1 β , IL-6, IL-10, INF- γ , TNF- α , GM-CSF, IL-8 or MCP-1.
7. (Withdrawn) A medicament useful for preventing or treating systemic inflammatory response syndrome not caused by an infection, comprising as an active ingredient at least one of riboflavin, a riboflavin derivative or a pharmacologically acceptable salt thereof.

8. (Withdrawn) The medicament according to Claim 7, wherein said systemic inflammatory response syndrome is caused by a wound, a burn, pancreatitis, liver damage, ischemia-reperfusion injury or surgery.

9. (Withdrawn) The medicament according to Claim 1, wherein said riboflavin derivative or pharmacologically acceptable salt thereof is flavin mononucleotide, flavin adenine dinucleotide, riboflavin tetrabutylate, riboflavin sodium phosphate, riboflavin phosphate monodiethanolamine salt, leucoflavin, monohydroflavin, leucoflavin phosphoric acid ester, leucoflavin mononucleotide, leucoflavin adenine dinucleotide or a pharmacologically acceptable salt thereof.

10. (Withdrawn) The medicament according to Claim 1, wherein at least one of the riboflavin, riboflavin derivative or pharmacologically acceptable salt thereof is contained in the form of an injection, tablet, granule, powder, subtle granule, capsule, pill or oral liquid.

11. (Withdrawn) The medicament according to Claim 1, wherein said cytokine suppression effect has as one mechanism the scavenging action of active oxygen.

12. (Withdrawn) A use of at least one of riboflavin, a riboflavin derivative or a pharmacologically acceptable salt thereof for preparation of a preventative or a therapeutic agent for hypercytokinemia.

13. (Canceled)

14. (Withdrawn) A cytokine suppressing agent, comprising as an active ingredient at least one of riboflavin, a riboflavin derivative or a pharmacologically acceptable salt thereof.

15. (Currently amended) A method for [[preventing or]]treating hypercytokinemia, comprising administering to a subject in need of such a treatment an effective dose of at least one

of riboflavin, a riboflavin derivative or a pharmacologically acceptable salt thereof to increase the survival rate of the subject.

16. (New) The method of claim 15, wherein the riboflavin, riboflavin derivative or pharmacologically acceptable salt thereof is riboflavin or a pharmacologically acceptable salt thereof.

17. (New) The method of claim 15, wherein the pharmacologically acceptable salt thereof is riboflavin sodium phosphate.

18. (New) The method of Claim 15, wherein the riboflavin derivative or pharmacologically acceptable salt thereof is flavin mononucleotide, flavin adenine dinucleotide, riboflavin tetrabutylate, riboflavin sodium phosphate, riboflavin phosphate monodiethanolamine salt, leucoflavin, monohydroflavin, leucoflavin phosphoric acid ester, leucoflavin mononucleotide, leucoflavin adenine dinucleotide or a pharmacologically acceptable salt thereof.

19. (New) The method of claim 15, wherein the riboflavin, riboflavin derivative or pharmacologically acceptable salt thereof is in the form of an injection, tablet, granule, powder, subtle granule, capsule, pill, or oral liquid.